Research map: Challenges and Opportunities for Signal Detection During Public Health Emergencies: An Historical Re-evaluation of the Disproportionality Analysis of the ADR Reporting of Anti-COVID-19 Monoclonal Antibodies in Vigibase

Back to the article

Papers in this map

  1. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination · Nina Haagenrud Schultz · 2021 · 1512 citations · Cited by this paper
  2. Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group · 2026 · Related
  3. Quantitative signal detection using spontaneous ADR reporting · Andrew M. Bate · 2009 · 913 citations · Cited by this paper
  4. A Large Language Model for Extracting Post-marketing Adverse Drug Events from Clinical Notes in the Electronic Health Record · 2026 · Related
  5. Tackling COVID-19 with neutralizing monoclonal antibodies · Davide Corti · 2021 · 420 citations · Cited by this paper
  6. Pharmacovigilance Through Fresh Eyes: The International Society of Pharmacovigilance Student Community's Role in Shaping the Future of Pharmacovigilance · 2026 · Related
  7. Case–non-case studies: Principle, methods, bias and interpretation · Jean‐Luc Faillie · 2019 · 330 citations · Cited by this paper
  8. Reliability of Self-Reported Maternal Health and Mother–Infant Outcome Data in Web-Based Questionnaires · 2026 · Related
  9. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants · Emi Takashita · 2022 · 328 citations · Cited by this paper
  10. Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant · 2026 · Related
  11. Monoclonal antibody therapies against SARS-CoV-2 · Daniele Focosi · 2022 · 286 citations · Cited by this paper
  12. MCSG: A Method for Simultaneous Disproportionality Analysis and Background Rate Estimation in Large Pharmacovigilance Databases · 2025 · Related
  13. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems · Paola Maria Cutroneo · 2024 · 204 citations · Cited by this paper
  14. Pharmacovigilance Due Diligence in Drug Development: A Practical Playbook for Risk Identification, Compliance Assessment, and Strategic Decision Making · 2025 · Related
  15. Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews · Stephanie Lucy Harrison · 2021 · 162 citations · Cited by this paper
  16. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines · Janet Sultana · 2020 · 143 citations · Cited by this paper
  17. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 · Gilmar Reis · 2021 · 142 citations · Cited by this paper
  18. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns · Anthony Touafchia · 2021 · 113 citations · Cited by this paper
  19. Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications · Lulu Ma · 2020 · 71 citations · Cited by this paper
  20. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database · Alexandre Olivier Gérard · 2020 · 71 citations · Cited by this paper
  21. Pharmacological treatment of COVID-19: an opinion paper · Alberto García‐Lledó · 2021 · 66 citations · Cited by this paper
  22. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System · Sara Cecco · 2024 · 51 citations · Cited by this paper
  23. Safety Monitoring of COVID ‐19 Vaccines: Perspective from the European Medicines Agency · Julie Durand · 2022 · 42 citations · Cited by this paper
  24. Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis · Meital Zur · 2023 · 31 citations · Cited by this paper
  25. Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance · Salvatore Crisafulli · 2025 · 30 citations · Cited by this paper
  26. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future · Marco Tuccori · 2021 · 29 citations · Cited by this paper
  27. Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization · Timothy S. Anderson · 2022 · 24 citations · Cited by this paper
  28. Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy · Daniele Focosi · 2022 · 23 citations · Cited by this paper
  29. Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project · Jason M. Devgun · 2023 · 21 citations · Cited by this paper
  30. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study · Min Seo Kim · 2021 · 19 citations · Cited by this paper
  31. Artificial intelligence for optimizing benefits and minimizing risks of pharmacological therapies: challenges and opportunities · Salvatore Crisafulli · 2024 · 18 citations · Cited by this paper
  32. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab–cilgavimab for coronavirus disease 2019 · François Montastruc · 2022 · 11 citations · Cited by this paper
  33. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy · Francesco Ciccimarra · 2023 · 7 citations · Cited by this paper
  34. A Short Update on the Use of Monoclonal Antibodies in COVID-19 · Antonio Vitiello · 2024 · 6 citations · Cited by this paper
  35. Transmissibility of the variant of concern for SARS-CoV-2 in six regions · Hongjie Wei · 2024 · 3 citations · Cited by this paper
  36. Cohort event monitoring of safety of COVID-19 vaccines: the Italian experience of the “ilmiovaccinoCOVID19 collaborating group” · Nicoletta Luxi · 2024 · 2 citations · Cited by this paper
  37. A review of methodologic & data considerations for vaccine safety surveillance in the wake of the COVID-19 pandemic · Katherine E. Mues · 2025 · 2 citations · Cited by this paper
  38. Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea · Ji Yeon Lee · 2023 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)